Lantheus (LNTH) vs Myriad Genetics (MYGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lantheus (LNTH) has outperformed Myriad Genetics (MYGN) over the past year, gaining 93.2% versus a loss of 43.2%. Over five years, LNTH leads with a +330.7% price change compared with -86.5% for MYGN. Lantheus is the larger company by market cap ($6.55 billion vs $394.1 million), about 16.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | MYGN |
|---|---|---|
| Share price | $100.27 | $4.12 |
| Market cap | $6.55B | $394.08M |
| 1-day change | +0.09% | -3.74% |
| YTD return | +50.53% | -30.41% |
| 1-year return | +93.25% | -43.16% |
| 5-year return | +330.70% | -86.52% |
| P/E ratio (TTM) | 24.28 | — |
| Forward P/E | 15.72 | — |
| EPS (TTM) | $4.13 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | — |
| Revenue growth (YoY) | +0.50% | — |
| Net income (latest FY) | $233.56M | — |
| Gross margin | 61.10% | — |
| Operating margin | 20.16% | — |
| Net margin | 15.15% | — |
| 52-week high | $111.86 | $8.59 |
| 52-week low | $50.16 | $2.74 |
| Distance from 52-week high | -10.36% | -52.04% |
| Analyst consensus | none | hold |
| Avg. price target upside | +7.45% | -5.10% |
| Average volume | 1.32M | 2.02M |
| Shares outstanding | 65.30M | 95.65M |
| Employees | 1,193 | 2,700 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Lantheus is about 16.6 times larger than Myriad Genetics by market value ($6.55B vs $394.08M).
- LNTH has outperformed MYGN by 136.4 percentage points over the past year.
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
LNTH vs MYGN FAQ
Which is bigger, Lantheus or Myriad Genetics?
Lantheus (LNTH) is larger, with a market capitalization of $6.55B compared with $394.08M for Myriad Genetics (MYGN).
Which stock has performed better over the past year, LNTH or MYGN?
LNTH returned +93.25% over the past 12 months, compared with -43.16% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and Myriad Genetics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.